Longeveron Inc. (LGVN)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Longeveron Files S-1 to Register 30.9 Million Shares for Resale
# 🧾 What This Document Is This is an **S-1 Registration Statement**. Think of it as a "permission slip" from the SEC. It doesn't mean Longeveron is selling new shares to raise money for itself right now. Instead, it's registering **30.9 million existing shares** so that certain investors (the "Sel
SEC filings
All filings →Insider trades
All insider trades →Longeveron Inc. has no reported insider trades in the last 90 days.